• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login

    Investing News NetworkYour trusted source for investing success

    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Australia Market
    Australia News
    Australia Stocks
    • Australia Market
    • Australia News
    • Australia Stocks
    1. Home>
    2. Australia Investing>
    Loading...
    0

    Australian Cannabis Trends 2021: Adoption Growing, Regulatory Changes Still Needed

    Bryan Mc Govern
    Jan. 26, 2022 01:30PM PST

    For the Australian cannabis market, 2021 was all about incremental growth as the industry continued to find its place in the global market.

    sydney opera house
    Rijan Hamidovic / Pexels

    Click here to read the previous Australian cannabis trends article.

    The Australian cannabis market experienced a busy 2021 period marked by significant challenges as players in the industry continued to look for opportunities.

    It’s all been about growth in the market, whether it comes from operations or regulations, as Australia continues to see its domestic market expand while players in the country pursue international ventures.

    Sentiment surrounding cannabis investment around the globe went through ups and downs in 2021, an effect that’s been reflected in Australia, but on the whole experts continue to point to a glowing future for the market.


    Australian cannabis trends 2021: New batch of numbers points to growth

    According to a report from FreshLeaf Analytics on how the Australian cannabis industry fared in the second half of 2021, revenue for the domestic market came in at AU$230 million for the year.

    Alongside the financial increase for the market there was a substantial uptick in patient count. Nearly 100,000 patients were expected to be registered in the Australian system by the end of the year, as per FreshLeaf.

    Each one of these patients spends, on average, AU$278 per month on medical cannabis.

    The research firm explains that its methodology accounts for patients “who have filled a prescription or consulted with a doctor about medicinal cannabis in the past six months.”

    Australia's patient growth indicates a key change in perspective on the medical applications of cannabis, with experts continuing to note that this is a slow-moving process that will pay off in the long run.

    "(Medical professionals) haven't gone through that usual path of learning about how cannabinoids work, what you prescribe them for, how you prescribe them, what you should be monitoring for in terms of adverse events and side effects," Dr. Yvonne Bonomo told ABC News. Dr. Bonomo is a physician and researcher at the Australian Centre for Cannabinoid Clinical and Research Excellence.

    Australian cannabis trends 2021: Regulations still complicated despite progress

    On a similar note, a report from Forbes indicates that public support for cannabis in Australia has gone up as general understanding of the drug continues to increase.

    Specifically, 41.1 percent of Australians are now in support of legalizing recreational cannabis use, according to the National Drug Strategy Household Survey. The most recent results are from 2019.

    While current regulations don't allow for adult use and place heavy restrictions on medical applications, access to medical cannabis has gradually improved as clinicians register as authorised prescribers.

    In 2021, authorised prescribers saw major growth. FreshLeaf Analytics states that at the end of September 2021, 430 doctors were allowed to prescribe the drug, a 40 percent increase from only three months before.

    “There is clearly a growing subset of clinicians who are committed to utilising medical cannabis as a regular treatment option for their patients,” the report from the Australian analytics firm explains.

    In an interview with ABC News, Josie Hamlett, compliance and logistics officer with domestic producer Tasmanian Botanics, said that despite all the progress seen in the market, it's challenging to manage a cannabis operation in the country due to the current landscape of regulation.

    "We definitely have a lot of hoops to jump through, working in the industry that we do ... particularly in some cases when federal and state legislation doesn't align," Hamlett said.

    Australian cannabis trends 2021: Investor takeaway

    Australia’s cannabis market continues to show signs of improvement, and it also has the numbers to back it up. Even so, the domestic landscape has a long way to go to reach maturity — education of the public and regulatory progress at the governmental level will be key moving forward.

    Don’t forget to follow us @INN_Australia for real-time news updates!

    Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

    From Your Site Articles
    • How to Access Medical Cannabis in Australia - Investing News ... ›
    • When Will Australia Legalise Recreational Cannabis? - Investing ... ›
    • Top 3 ASX Cannabis Stocks (Updated January 2022) - Investing ... ›
    • | Cannabis Stocks in Australia | INN - Investing News Australia ›
    • Guide to Cannabis in Australia | States and Territories | INN ... ›
    https://www.linkedin.com/in/bryan-mc-govern-b23495b0/
    bmcgovern@investingnews.com
    The Conversation (0)
    Go Deeper
    AI Powered
    Cannabis leaf over map of Australia.

    A State-by-State Guide to Cannabis in Australia

    Person touching a cannabis plant; Australia map in flag colours.

    ASX Cannabis Stocks: 10 Biggest Companies

    Bryan Mc Govern

    Bryan Mc Govern

    Senior Editor

    Bryan is a Senior Editor with INN. After graduating from the Langara journalism program he did some freelance reporting with community newspapers in British Columbia. He initially wrote about the life science space for INN and now spends his time covering the marijuana market, from Canadian LPs to US-based companies, and the impact of this sector on investors.

    Latest News

    Blackstone Completes Share Purchase Plan

    Quarterly Activities/Appendix 4C Cash Flow Report

    Reinstatement to Quotation

    Agreement to Develop New Expandable Graphite Facility

    Comet share sale and debt repayment

    More News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Australia Investing Stocks

    extractX

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×
    Bryan Mc Govern

    Bryan Mc Govern

    Senior Editor

    Bryan is a Senior Editor with INN. After graduating from the Langara journalism program he did some freelance reporting with community newspapers in British Columbia. He initially wrote about the life science space for INN and now spends his time covering the marijuana market, from Canadian LPs to US-based companies, and the impact of this sector on investors.

    Full Bio

    Follow

    Learn about our editorial policies.